OncoMatch/Clinical Trials/NCT06157541
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Is NCT06157541 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Allogeneic cytomegalovirus-specific T cells and Pembrolizumab for glioblastoma multiforme.
Treatment: Allogeneic cytomegalovirus-specific T cells · Pembrolizumab — The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus \[CMV\]-specific T cells and pembrolizumab) in patients with brain cancer. The type of brain cancer being studied is glioblastoma multiforme/astrocytoma grade 4. The purpose of part 1 of this study is to determine the maximum-tolerated dose and/or recommended dose(s) for future exploration of allogeneic CMV-specific T cells as monotherapy or in combination with pembrolizumab in patients with recurrent GBM/astrocytoma grade 4. Part 2 of the study aims to investigate the anti-tumour activity of allogeneic CMV-specific T cells as monotherapy or in combination with pembrolizumab, assessed by magnetic resonance imaging and survival, in patients with recurrent or newly diagnosed GBM/grade 4 astrocytoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
Cannot have received: systemic anti-cancer therapy or investigational agents
Exception: temozolomide permitted during the trial
Has received prior systemic anti-cancer therapy or investigational agents within 4 weeks prior to study intervention, with the exception of temozolomide, which is permitted during the trial
Cannot have received: live vaccine
Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study intervention
Cannot have received: investigational agent/device
Has received in an investigational agent, or has used an investigational device within 4 weeks prior to the first dose of study intervention
Lab requirements
Blood counts
adequate organ function required; specimens must be collected within 10 days prior to the start of study intervention
Kidney function
adequate organ function required; specimens must be collected within 10 days prior to the start of study intervention
Liver function
adequate organ function required; specimens must be collected within 10 days prior to the start of study intervention
Have adequate organ function. Specimens must be collected within 10 days prior to the start of study intervention.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify